Does hemodilution enhance or compromise blood coagulation?

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 1, Issue 4, 1997, Pages 342-348

  Egli, Gabi A ^a   Spahn, Donat R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001561495     PISSN: 10892532     EISSN: 19405596     Source Type: Journal    
DOI: 10.1177/108925329700100407     Document Type: Article

References (68)

1. A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy: Practice guidelines for blood component therapy. Anesthesiology 84:732-47,1996.
2. Rutherford CJ, Kaplan HS: Autologous blood donations- Can we bank on it? N Engl J Med 332:740-742, 1995 (editorial).
3. Spahn DR, Schmid ER: Haemodilution in cardiac and vascular surgery. Curr Opin Anaesthesiol 9:54-61, 1996.
4. Spahn DR, Leone BJ, Reves JG,et al:Cardiovascular and coronary physiology of acute isovolemic hemodilution: A review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg 78:1000-1021,1994.
5. Jurecka W., Szepfalusi Z., Parth E.,et al:Hydroxyethyl-starch deposits in human skin-A model for pruritus? Arch Dermatol Res 285:13-19, 1993.
6. Looker D., Abbott-Brown D., Cozart P.,et al:A human recombinant haemoglobin designed for use as a blood substitute. Nature 356:258-260,1992.
7. Keipert PE, Faithfull NS, Bradley JD,et al:Oxygen delivery augmentation by low-dose perfluorochemical emulsion during profound normovolemic hemodilution. Adv Exp Med Biol 345:197-204,1994.
8. McLoughlin TM, Fontana JL, Alving B.,et al:Profound normovolemic hemodilution: Hemostatic effects in patients and in a porcine model. Anesth Analg 83:459-465, 1996.
9. Furie B., Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 326:800-806, 1992.
10. Ruttmann TG, James Mfm, Viljoen JF: Haemodilution induces a hypercoagulable state. Br J Anaesth 76:412-414, 1996.
11. Janvrin SB, Davies G., Greenhalgh RM: Postoperative deep vein thrombosis caused by intravenous fluids during surgery. Br J Surg 67:690-693, 1980.
12. Ng KF, Lo JW: The development of hypercoagulability state, as measured by thromboelastography, associated with intraoperative surgical blood loss. Anaesth Intens Care 24:20-25, 1996.
13. Tuman KJ, Spiess BD, McCarthy RJ,et al:Effects of progressive blood loss on coagulation as measured by thromboelastography. Anesth Analg 66:856-863, 1987.
14. Stump DC, Strauss RG, Henriksen RA,et al:Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 25:349-354, 1985.
15. Korttila K., Gröhn P., Gordin A.,et al:Effect of hydroxyethyl starch and Dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 273-282, 1984.
16. Harke H., Thoenies R., Margraf I.,et al:Der Einfluss verschiedener Plasmaersatzmittel auf Gerinnungssystem und Thrombocytenfunktion während und nach operativen Eingriffen. Anaesthesist 25:366-373, 1976.
17. Egli GA, Zollinger A., Seifert B.,et al:Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. An in vitro thromboelastography study. Br J Anaesth 78:684-689, 1997.
18. Tocantins LM, Carroll RT, Holburn RH: The clot accelerating effect of dilution on blood and plasma. Relation to the mechanism of coagulation of normal and hemophilic blood. Blood 6:720-739, 1950.
19. Bowens C., Spahn DR, Frasco PE,et al:Hemodilution induces stable changes in global cardiovascular and regional myocardial function. Anesth Analg 76:1027-1032, 1993.
20. Uza G., Crisnic I.: Effect of angiotensin II upon platelet adhesiveness and the Thrombelastogram in patients with essential arterial hypertension. Pathol Eur 10:327-332, 1975.
21. Barrer MJ, Ellison N.: Platelet function. Anesthesiology 46:202-211, 1977.
22. Bernstein CA, Waters JH: Thromboelastographic change following hetastarch or albumin. Anesth Analg 82:S25, 1996 (abstr).
23. Strauss RG: Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21:299-302,1981.
24. Boldt J., Knothe C., Zickmann B.,et al:Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185-1190, 1993.
25. Gold MS, Russo J., Tissot M.,et al:Comparison of hetastarch to albumin for perioperative bleeding in patients undergoing abdominal aortic aneurysm surgery. A prospective, randomized study. Ann Surg 211:482-485, 1990.
26. Aberg M., Hedner U., Bergentz SE: The antithrombotic effect of Dextran. Scand J Haematol 34:61-68, 1979 (suppl).
27. Cronberg S., Robertson B., Nilsson IM,et al:Suppressive effect of Dextran on platelet adhesiveness. Thromb Diath Haemorrh 16:384-394, 1966.
28. Harke H., Pieper C., Meredig J.,et al:Rheologische und gerinnungsphysiologische Untersuchungen nach Infusion von HAES 200/0.5 and Dextran 40. Eine vergleichende klinische Studie. Anaesthesist 29:71-77, 1980.
29. Batlle J., del-Rio F., Lopez-Fernandez MF,et al:Effect of Dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost 54:697-699, 1985.
30. Bergqvist D.: Dextran and haemostasis. A review. Acta Chir Scand 148:633-640, 1982.
31. Bergentz SE, Eiken O., Nilsson IM: The effect of Dextran of various molecular weight on the coagulation in dogs. Thromb Diath Haemorrh 6:15-24, 1961.
32. Bergqvist D.: The influence of plasma volume expanders on initial haemostasis in the rabbit mesentery. Acta Anaesthesiol Scand 29:607-609, 1985.
33. Carbone JV, Furth FW, Scott R.,et al:An hemostatic defect associated with Dextran infusion. Proc Soc Exp Biol 101-103, 1954.
34. Alexander B.: Effects of plasma expanders on coagulation and hemostasis: Dextran hydroxyethyl starch, and other macromolecules revisited. Prog Clin Biol Res 19:293-330, 1978.
35. Carr ME, Gabriel DA: The effect of Dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 96:985-993, 1980.
36. Aberg M., Bergentz SE, Hedner U.: The effect of Dextran on the lysability of ex vivo thrombi. Ann Surg 181:342-345, 1975.
37. Carlin G., Bang NU: Enhancement of plasminogen activation and hydrolysis of purified fibrinogen and fibrin by Dextran 70. Thromb Res 19:535-546, 1980.
38. London MJ, Ho JS, Triedman JK,et al:A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 97:785-797, 1989.
39. Strauss RG, Stansfield C., Henriksen RA,et al:Pentastarch may cause fewer effects on coagulation than hetastarch. Transfusion 28:257-260, 1988.
40. Kuitunen A., Hynynen M., Salmenpera M.,et al:Hydroxyethyl starch as a prime for cardiopulmonary bypass: Effects of two different solutions on haemostasis. Acta Anaesthesiol Scand 37:652-658, 1993.
41. Treib J., Haass A., Pindur G.,et al:All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 36:450-455, 1996.
42. Treib J., Haass A., Pindur G.,et al:HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorrheology, coagulation and elimination kinetics. Thromb Haemost 74: 1452-1456, 1995.
43. Lockwood DN, Bullen C., Machin SJ: A severe coagulopathy following volume replacement with hydroxyethyl starch in a Jehovah's Witness. Anaesthesia 43:391-393, 1988.
44. Sanfelippo MJ, Suberviola PD, Geimer NF: Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pathol 88:653-655, 1987.
45. Kapiotis S., Quehenberger P., Eichler HG,et al:Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: Comparison with albumin. Crit Care Med 22:606-612, 1994.
46. Gollub S., Schaefer C., Squitieri A.: The bleeding tendency associated with plasma expanders. Surg Gynecol Obstet 124:1203-1211, 1967.
47. Garzon AA, Cheng C., Lerner B.,et al:Hydroxyethyl starch (HES) and bleeding. An experimental investigation of its effect on hemostasis. J Trauma 7:757-766, 1967.
48. Carr ME: Effect of hydroxyethyl starch on the structure of thrombin- and reptilase-induced fibrin gels. J Lab Clin Med 108:556-561, 1986.
49. Strauss RG, Stump DC, Henriksen RA,et al:Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 25:230-234, 1985.
50. Tschirren B., Pfistner P.: Praktische Erfahrungen mit Physiogel als Blutersatzstoff. Helv Chir Acta 33:404-414, 1966.
51. Tabuchi N., De Haan J., Huet RC,et al:Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 74:1447-1451, 1995.
52. Mortelmans YJ, Vermaut G., Verbruggen AM,et al:Effects of 6% hydroxethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg 81:1235-1242, 1995.
53. Heene DL, Lasch HG: The effect of gelatin plasma substitutes on the hemostatic mechanism. Bibl Haematol 33:428-433, 1969.
54. Mardel SN, Saunders F., Ollerenshaw L.,et al:Reduced quality of in-vitro clot formation with gelatin-based plasma substitutes. Lancet 347:825, 1996 (letter).
55. Huskisson L.: Intravenous volume replacement: Which fluid and why? Arch Dis Child 67:649-653, 1992.
56. Griffel MI, Kaufman BS: Pharmacology of colloids and crystalloids. Crit Care Clin 8:235-253, 1992.
57. Salmon JB, Mythen MG: Pharmacology and physiology of colloids. Blood Rev 7:114-120, 1993.
58. Funk W., Baldinger V.: Microcirculatory perfusion during volume therapy. A comparative study using crystalloid or colloid in awake animals. Anesthesiology 82:975-982, 1995.
59. Traylor RJ, Pearl RG: Crystalloid versus colloid versus colloid: All colloids are not created equal. Anesth Analg 83:209-212, 1996 (editorial).
60. Ring J.: Anaphylactoid reactions to intravenous solutions used for volume substitution. Clin Rev Allergy 9:397-414, 1991.
61. Laxenaire MC, Charpentier C., Feldman L.: Réactions anaphylactoïdes aux substituts colloïdaux du plasma: Incidence, facteurs de risque, mécanismes. Enquête prospective multicentrique française. Ann Fr Anesth Reanim 13:301-310, 1994.
62. Bonnar J., Walsh J.: Prevention of thrombosis after pelvic surgery by British Dextran 70. Lancet 1:614-616, 1972.
63. Halonen P., Linko K., Myllyla G.: A study of haemostasis following the use of high doses of hydroxyethyl starch 120 and Dextran in major laparotomies. Acta Anaesthesiol Scand 31:320-324, 1987.
64. Sirtl C., Kraft D., Zumtobel V.,et al:Tissue storage of hydroxyethyl starch-A temporarily limited phenomenon? Anesthesiology 85:A255, 1996 (abstr).
65. Siegel MN, Bjoraker DG, Gravenstein N.,et al:Changes in clot formation induced by hydroxyethyl starch and Dextran-40: Assessment by Thrombelastograph and Sonoclot. Anesthesiology 69:A13, 1988 (abstr).
66. Dietrich G., Orth D., Haupt W.,et al:Primary hemostasis in hemodilution-2) Infusion solutions. Infusionstherapie 17:214-216,1990.
67. Aberg M., Hedner U., Bergentz SE: Effect of Dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 189:243-247, 1979.
68. Garzon AA, Fink LH, Shaftan GW,et al:Blood loss associated with administration of low-molecular-weight Dextran. J Thorac Cardiovasc Surg 48:873-880, 1964.